attention deficit hyperactivity disorder
Neurology · 2005–2020
6decisions
4medicines
1carried consumer input
18individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| methylphenidate hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years who have demonstrated a response to immediate-release… | Mar 2020 | Recommended | 18 individuals |
| guanfacine Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years who are contraindicated to stimulants, intolerant to… | Jul 2017 | Recommended with restriction | none received |
| atomoxetine hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in patients diagnosed between ages 6 and 18 years inclusive by a paediatrician or psychiatrist,… | Jul 2008 | Recommended with restriction | no section in document |
| methylphenidate hydrochloride, extended release Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-18 years who require continuous coverage over 12 hours. | Mar 2006 | Not recommended | no section in document |
| methylphenidate hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-18 years who require continuous coverage over 12 hours. | Mar 2006 | Not recommended | no section in document |
| atomoxetine hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years diagnosed by a paediatrician or psychiatrist according… | Nov 2005 | Not recommended | no section in document |
What the PBS pays
$97M in government benefit over 2024–25, across 2,515,675 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| methylphenidate hydrochloride | $58.8M |
| guanfacine | $33.5M |
| atomoxetine hydrochloride | $4.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.